Objectif In order to be fully effective as an oncolytic virus or vaccine, achieving of precise and specific traits are pivotal. However, current technologies are limited to the confines of a virus’s existing biological make-up. They are left with manipulation of genes within the virus e.g. deleting and adding proteins, inability to manipulate silent codes etc. where achievement of such precision is simply not possible from such naturally-rooted manipulation.The SynVaccine solution taps into 3 billion years of viral evolutionary data which is continually updated, ensuring the highest degree of accuracy on rules that govern all viruses found today. Through this, it becomes the only solution to govern the rules of viruses on a cellular level, giving the important ability to precisely dictate the traits and behaviour of the newly designed, bottom-up, created viruses. As a result, only the most effective oncolytic viruses and vaccines are ever produced, ensuring the highest levels of treatment and immunity.We have invested over €3.1 million into the development and testing of our solution to ensure its robustness and efficiency, and thus move into the next stage of specific drug development. Our management and scientific leadership capacity involves 10 multi-disciplinary experts in the fields of; entrepreneurship, virology, synthetic biology, computational biology, engineering and automation.The proposed work in Phase 1 of the SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of our SynVaccine derived solutions, and their market uptake. Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverynatural sciencesbiological sciencesmicrobiologyvirologymedical and health sciencesbasic medicineimmunologymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesmedical and health sciencesclinical medicineoncology Programme(s) H2020-EU.2.1.4. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Thème(s) SMEInst-03-2016-2017 - Dedicated support to biotechnology SMEs closing the gap from lab to market Appel à propositions H2020-SMEInst-2016-2017 Voir d’autres projets de cet appel Sous appel H2020-SMEINST-1-2016-2017 Régime de financement SME-1 - SME instrument phase 1 Coordinateur SYNVACCINE LTD Contribution nette de l'UE € 50 000,00 Adresse HABARZEL ST 27 6971039 Tel Aviv Israël Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 71 429,00
